Stock DERM JOURNEY MEDICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News Journey Medical Corporation

Equities

DERM

US48115J1097

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.33 USD -2.06% Intraday chart for Journey Medical Corporation -5.93% -42.19%
Mar. 21 Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024
Mar. 21 Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
AQ
Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
AQ
Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
AQ
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
CI
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
AQ
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 on Microbial Flora of Healthy Adults At 2024 Annual Meeting
CI
Alliance Global Partners Starts Coverage on Journey Medical With Buy Rating, $8.50 Price Target
MT
Journey Medical Submits New Drug Application to FDA for Rosacea Treatment; Shares Rise
MT
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
AQ
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
CI
Journey Medical Signs Credit Facility of up to $20 Million
MT
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
AQ
Journey Medical Corporation Secures Credit Facility with SWK Holdings for Up to $20 Million
CI
Journey Medical Corporation Announces Resignation of Jeffrey Paley as Member of the Board of Directors
CI
B. Riley Lifts Journey Medical's PT to $8 From $6 After US FDA Gives Green Light for DFD-29's Year-End 2023 Filing, Keeps Buy Rating
MT
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DERM Stock
  4. News Journey Medical Corporation